Unexplained weight loss (UWL) is a clinical conundrum that often presents a diagnostic challenge to physicians. It can be an indicator of a serious underlying condition, necessitating a comprehensive, systematic approach to accurately determine its etiology.
The first step in diagnosing UWL is a thorough history taking. This includes the patient's past medical history, lifestyle habits, medications, and psychosocial factors. A detailed dietary history can reveal potential causes such as malnutrition or malabsorption. The duration and rate of weight loss can also provide valuable clues.
A comprehensive physical examination is crucial to identify any abnormal findings suggestive of a specific disease. Basic investigations include complete blood counts, kidney and liver function tests, thyroid function tests, and a urinalysis. These can help rule out common causes of UWL like malignancies, endocrine disorders, and chronic infections.
If the initial investigations are inconclusive, further diagnostic testing may be warranted. This may include imaging studies, endoscopies, or biopsies, depending on the patient's symptoms and history. A multidisciplinary approach involving specialists such as gastroenterologists, endocrinologists, or oncologists may be necessary in complex cases.
It's important to consider non-organic causes of UWL, such as psychiatric disorders including depression and eating disorders. A psychiatric evaluation may be beneficial in these cases. Social factors, such as food insecurity or elder neglect, should also be considered.
Diagnosing UWL requires a systematic, comprehensive approach that includes a detailed history, physical examination, and appropriate investigations. Collaboration with specialists may be necessary. Understanding and identifying the cause of UWL is vital as it can be a sign of a serious underlying condition, warranting prompt treatment.
1.
Cancer tumor anatomy influences the benefits of chemotherapy for patients with early-stage breast cancer.
2.
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
3.
Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer
4.
In early dementia, SSRIs enhance cognition and major depression.
5.
TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL
1.
Oncologic Emergencies: Diagnosis and Treatment
2.
Strategic Standards in Hematology for Specialists
3.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
4.
Advanced Breakthroughs in Hematology and Patient Outcomes
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
3.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation